FindTrial
Sign In

Ubamatamab

DRUG8 trials

Sponsors

Regeneron Pharmaceuticals Inc., Regeneron Pharmaceuticals, M.D. Anderson Cancer Center

Conditions

Advanced/Metastatic Non-Small Cell Lung CancerEndometrial CancerEpithelioid SarcomaFallopian Tube CancerLow-grade Serous Ovarian CancerOvarian CancerPrimary Peritoneal CancerRecurrent Endometrial Cancer

Phase 1

Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers
RecruitingNCT03564340
Regeneron PharmaceuticalsEndometrial Cancer, Low-grade Serous Ovarian Cancer, Recurrent Endometrial Cancer +3
Start: 2018-05-21End: 2027-01-31Target: 890Updated: 2025-12-03
A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab
RecruitingNCT04590326
Regeneron PharmaceuticalsEndometrial Cancer, Fallopian Tube Cancer, Ovarian Cancer +1
Start: 2020-12-08End: 2027-11-30Target: 612Updated: 2025-11-21
A PHASE 1/2 STUDY OF REGN5668 (MUC16 × CD28, A COSTIMULATORY BISPECIFIC ANTIBODY) ADMINISTERED IN COMBINATION WITH OTHER AGENTS IN MUC16+ MALIGNANCIES
RecruitingCTIS2022-501904-83-00
Regeneron Pharmaceuticals Inc.Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cancer
Start: 2023-09-11Target: 208Updated: 2025-12-03
A Phase 1/2 Study of REGN4018 (Ubamatamab), a MUC16xCD3 Bispecific Antibody, Administered Alone or in Combination with Cemiplimab in Patients with Recurrent Ovarian Cancer or Other Recurrent MUC16+ Cancers
RecruitingCTIS2024-510783-23-00
Regeneron Pharmaceuticals Inc.Endometrial Cancer, Fallopian Tube Cancer, Ovarian Cancer +1
Start: 2020-10-29Target: 237Updated: 2025-12-11

Phase 2

Phase II Trial of Ubamatamab Alone or in Combination With Cemiplimab in MUC16-Expressing SMARCB1-Deficient Malignancies
RecruitingNCT06444880
M.D. Anderson Cancer CenterSMARCB1-Deficient Malignancies
Start: 2024-10-09End: 2028-07-31Target: 40Updated: 2026-01-08
Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer
RecruitingNCT06787612
Regeneron PharmaceuticalsFallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cancer
Start: 2025-05-28End: 2028-10-30Target: 220Updated: 2026-04-02
A Study to Investigate Ubamatamab With and Without REGN7075 in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
RecruitingNCT07154290
Regeneron PharmaceuticalsAdvanced/Metastatic Non-Small Cell Lung Cancer
Start: 2026-03-18End: 2030-06-24Target: 300Updated: 2026-03-27

Unknown Phase

Compassionate Use of Ubamatamab
NCT07502716
Regeneron PharmaceuticalsEpithelioid Sarcoma, Renal Medullary Carcinoma (RMC)
Updated: 2026-03-31

Related Papers

Mucin 16–Directed Therapy in Pediatric Sarcomas: Case Evidence of Ubamatamab Efficacy in Epithelioid Sarcoma and Its Implications for Other Sarcoma Subtypes
JCO Precision Oncology2025-08-011 citations
A phase 1/2 study of ubamatamab (REGN4018), a MUC16×CD3 bispecific antibody, administered alone or in combination with cemiplimab (anti–PD-1) in patients with recurrent ovarian cancer or MUC16+ endometrial cancer.
Journal of Clinical Oncology2024-06-018 citations
First-in-human phase 1/2 study of ubamatamab, a MUC16xCD3 bispecific antibody, administered alone or in combination with cemiplimab in patients with recurrent ovarian cancer.
Journal of Clinical Oncology2023-06-017 citations
A phase I/II, multicenter, open-label study of REGN5668 (mucin [MUC]16 x CD28 bispecific antibody [bsAb]) with cemiplimab (programmed death [PD]-1 Ab) or REGN4018 (MUC16 x CD3 bsAb) in recurrent ovarian cancer (rOVCA).
Journal of Clinical Oncology2021-05-205 citations